Successfully targeting the cancer system with metronomics for medulloblastoma
Copyright © 2023 Elsevier Inc. All rights reserved..
The prognosis of the patients with medulloblastoma who relapse after initial treatment including radiotherapy remains dismal. A recent study by Peyrl et al. in JAMA Oncology suggests that the metronomic multidrug combination used in the medulloblastoma European multitarget metronomic antiangiogenic trial (MEMMAT) given at relapse can improve long-term survival.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:9 |
|---|---|
| Enthalten in: |
Trends in cancer - 9(2023), 12 vom: 22. Dez., Seite 989-991 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
André, Nicolas [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Angiogenesis |
|---|
| Anmerkungen: |
Date Completed 27.11.2023 Date Revised 13.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.trecan.2023.10.004 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM364321407 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM364321407 | ||
| 003 | DE-627 | ||
| 005 | 20240313233753.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.trecan.2023.10.004 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1326.xml |
| 035 | |a (DE-627)NLM364321407 | ||
| 035 | |a (NLM)37940401 | ||
| 035 | |a (PII)S2405-8033(23)00215-7 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a André, Nicolas |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Successfully targeting the cancer system with metronomics for medulloblastoma |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 27.11.2023 | ||
| 500 | |a Date Revised 13.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 Elsevier Inc. All rights reserved. | ||
| 520 | |a The prognosis of the patients with medulloblastoma who relapse after initial treatment including radiotherapy remains dismal. A recent study by Peyrl et al. in JAMA Oncology suggests that the metronomic multidrug combination used in the medulloblastoma European multitarget metronomic antiangiogenic trial (MEMMAT) given at relapse can improve long-term survival | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a angiogenesis | |
| 650 | 4 | |a cancer | |
| 650 | 4 | |a cancer system | |
| 650 | 4 | |a children | |
| 650 | 4 | |a drug repurposing | |
| 650 | 4 | |a immune system | |
| 650 | 4 | |a medulloblastoma | |
| 650 | 4 | |a metronomic chemotherapy | |
| 700 | 1 | |a Bailey, Simon |e verfasserin |4 aut | |
| 700 | 1 | |a Peyrl, Andreas |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Trends in cancer |d 2015 |g 9(2023), 12 vom: 22. Dez., Seite 989-991 |w (DE-627)NLM253590183 |x 2405-8025 |7 nnns |
| 773 | 1 | 8 | |g volume:9 |g year:2023 |g number:12 |g day:22 |g month:12 |g pages:989-991 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.trecan.2023.10.004 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 9 |j 2023 |e 12 |b 22 |c 12 |h 989-991 | ||